[go: up one dir, main page]

MX2010008817A - Tratamiento de cancer de prostata en etapa metastatica con degarelix. - Google Patents

Tratamiento de cancer de prostata en etapa metastatica con degarelix.

Info

Publication number
MX2010008817A
MX2010008817A MX2010008817A MX2010008817A MX2010008817A MX 2010008817 A MX2010008817 A MX 2010008817A MX 2010008817 A MX2010008817 A MX 2010008817A MX 2010008817 A MX2010008817 A MX 2010008817A MX 2010008817 A MX2010008817 A MX 2010008817A
Authority
MX
Mexico
Prior art keywords
degarelix
treatment
prostate cancer
stage prostate
metastatic stage
Prior art date
Application number
MX2010008817A
Other languages
English (en)
Inventor
Bo-Eric Persson
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39718285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010008817(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Publication of MX2010008817A publication Critical patent/MX2010008817A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se proporcionan composiciones que comprenden degarelix para el tratamiento del cáncer de próstata en etapa metastática en un sujeto. La figura más representativa de la invención es la número 1.
MX2010008817A 2008-02-11 2009-02-10 Tratamiento de cancer de prostata en etapa metastatica con degarelix. MX2010008817A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2774108P 2008-02-11 2008-02-11
EP08250703 2008-02-29
US14795609P 2009-01-28 2009-01-28
PCT/IB2009/000370 WO2009101533A1 (en) 2008-02-11 2009-02-10 Treatment of metastatic stage prostate cancer with degarelix

Publications (1)

Publication Number Publication Date
MX2010008817A true MX2010008817A (es) 2010-09-09

Family

ID=39718285

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010008816A MX2010008816A (es) 2008-02-11 2009-02-10 Metodo para tratar el cancer de prostata con el antagonista de gnrh degarelix.
MX2010008817A MX2010008817A (es) 2008-02-11 2009-02-10 Tratamiento de cancer de prostata en etapa metastatica con degarelix.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010008816A MX2010008816A (es) 2008-02-11 2009-02-10 Metodo para tratar el cancer de prostata con el antagonista de gnrh degarelix.

Country Status (25)

Country Link
US (17) US8841081B2 (es)
EP (7) EP4257197A3 (es)
JP (11) JP5876652B2 (es)
KR (8) KR20230088848A (es)
CN (4) CN101998861A (es)
AU (2) AU2009213748B9 (es)
BR (2) BRPI0908129A2 (es)
CA (3) CA3235099A1 (es)
CY (3) CY1115561T1 (es)
DK (3) DK2650012T3 (es)
EA (4) EA020543B1 (es)
ES (3) ES2540235T3 (es)
HK (1) HK1198243A1 (es)
HR (3) HRP20140665T1 (es)
IL (3) IL207295A (es)
JO (1) JOP20090061B1 (es)
MX (2) MX2010008816A (es)
NZ (4) NZ587088A (es)
PL (3) PL2505204T3 (es)
PT (3) PT2505204E (es)
RU (2) RU2504393C2 (es)
SI (3) SI2505204T1 (es)
TW (2) TWI539959B (es)
WO (2) WO2009101533A1 (es)
ZA (1) ZA201005697B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
JO3525B1 (ar) * 2008-02-11 2020-07-05 Ferring Int Center Sa علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس
BRPI1010874A8 (pt) * 2009-05-01 2018-01-02 Ferring Bv composição para o tratamento de câncer de próstata
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
FR2964323B1 (fr) * 2010-09-08 2012-11-09 Jean Pierre Raynaud Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
WO2012055903A1 (en) 2010-10-27 2012-05-03 Ferring B.V. Process for the manufacture of degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
EP2683643B1 (en) 2011-03-09 2019-05-08 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
WO2013173312A1 (en) 2012-05-14 2013-11-21 Pestell Richard G Using modulators of ccr5 for treating cancer
NZ727679A (en) 2012-06-01 2018-05-25 Ferring Bv Manufacture of degarelix
UA117663C2 (uk) 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
CN113372358B (zh) 2012-09-28 2024-05-14 武田药品工业株式会社 噻吩并嘧啶衍生物的制备方法
EP3384930A1 (en) 2013-03-15 2018-10-10 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding
WO2014186608A1 (en) * 2013-05-15 2014-11-20 Adverse Events, Inc. System and method for surveillance and evaluation of safety risks associated with medical interventions
AU2015308987B2 (en) * 2014-08-26 2021-02-18 Kaass Discovery As Methods, agents and compositions for treatment of inflammatory conditions
EP3294301A4 (en) * 2015-05-12 2019-01-09 Drexel University COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CANCER METASTAS AND METHODS THEREWITH
AU2017334035B2 (en) 2016-09-30 2022-11-24 Sumitomo Pharma Switzerland Gmbh Treatment of prostate cancer
CN110248679A (zh) * 2017-01-30 2019-09-17 安迪威有限公司 包含至少一种GnRH拮抗剂的组合物
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
AU2018419533A1 (en) 2018-04-19 2020-11-12 Abbvie Inc. Methods of treating heavy menstrual bleeding
AU2019315522A1 (en) * 2018-08-01 2021-02-18 Abbvie Inc. Dosing regimens for elagolix
RU2731002C1 (ru) * 2019-10-22 2020-08-26 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения рака предстательной железы
CN116407494B (zh) * 2023-03-02 2024-07-09 山东大学齐鲁医院 一种醋酸地加瑞克注射液及其制备方法、用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ZA735680B (en) * 1972-09-21 1974-07-31 Hoffmann La Roche Polypeptides
US4072668A (en) 1973-11-06 1978-02-07 The Salk Institute For Biological Studies LH-RH Analogs
EP0002749B2 (en) 1977-12-26 1987-08-12 IHARA CHEMICAL INDUSTRY Co., Ltd. Process for producing aromatic monocarboxylic acid
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
ATE144538T1 (de) 1991-04-25 1996-11-15 Romano Deghenghi Lhrh-antagonisten
ES2159516T5 (es) 1992-02-12 2005-05-01 Daikyo Gomu Seiko Ltd. Un instrumento medico.
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5825730A (en) 1995-03-10 1998-10-20 Kabushiki Kaisha Toshiba Mastering machine having non-repetitive runout compensation
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
US5710246A (en) 1996-03-19 1998-01-20 Abbott Laboratories Process for intermediates for the synthesis of LHRH antagonists
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
WO1999026964A1 (en) 1997-11-20 1999-06-03 Ortho-Mcneil Pharmaceutical, Inc. LIQUID PHASE PROCESS FOR THE PREPARATION OF GnRH PEPTIDES
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US6913761B1 (en) 1998-07-20 2005-07-05 Peptech Limited Bioimplant formulation
ES2312435T3 (es) * 2000-03-14 2009-03-01 Aeterna Zentaris Gmbh Antagonistas de lhrh, su preparacion y su uso como medicamentos.
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
IL158969A0 (en) * 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070015713A1 (en) 2005-07-14 2007-01-18 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
US20060234918A1 (en) * 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
SE0104463D0 (sv) 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
MXPA05003318A (es) 2002-09-27 2005-09-12 Zentaris Gmbh Forma de administracion para peptidos farmaceuticamente activos con liberacion sostenida y metodo para la produccion de los mismos.
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006069779A1 (en) 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
WO2009048932A2 (en) 2007-10-09 2009-04-16 Children's Medical Center Corporation Methods to regulate mirna processing by targeting lin-28
KR20100120289A (ko) 2008-01-15 2010-11-15 애보트 게엠베하 운트 콤파니 카게 분말상 단백질 조성물 및 이의 제조 방법
TWI539959B (zh) * 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
US8105292B2 (en) 2008-02-11 2012-01-31 Safety Syringes, Inc. Reconstitution means for safety device
DK2421887T3 (en) 2009-04-24 2015-07-27 Polypeptide Laboratories As A process for the preparation of degarelix
BRPI1010874A8 (pt) 2009-05-01 2018-01-02 Ferring Bv composição para o tratamento de câncer de próstata
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
WO2012055903A1 (en) 2010-10-27 2012-05-03 Ferring B.V. Process for the manufacture of degarelix and its intermediates
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN102204889B (zh) 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
CN103841970A (zh) 2011-07-15 2014-06-04 辉凌公司 其中施用匹可硫酸盐组合物的结肠镜检查定时方法
NZ727679A (en) 2012-06-01 2018-05-25 Ferring Bv Manufacture of degarelix

Also Published As

Publication number Publication date
PT2505204E (pt) 2015-03-26
RU2504394C2 (ru) 2014-01-20
KR101542480B1 (ko) 2015-08-07
US20130029910A1 (en) 2013-01-31
SI2249859T1 (sl) 2014-08-29
PT2249859E (pt) 2014-07-31
CN101998861A (zh) 2011-03-30
EA020543B1 (ru) 2014-12-30
US20090203623A1 (en) 2009-08-13
HRP20150633T1 (hr) 2015-07-31
KR20230088848A (ko) 2023-06-20
EP2799085A1 (en) 2014-11-05
US8841081B2 (en) 2014-09-23
EP4257197A3 (en) 2023-11-29
US20170035833A1 (en) 2017-02-09
US20220323538A1 (en) 2022-10-13
US20220218783A1 (en) 2022-07-14
EP4257197A2 (en) 2023-10-11
HK1190912A1 (en) 2014-07-18
EA200901074A1 (ru) 2010-04-30
US20140113870A1 (en) 2014-04-24
US20250134948A1 (en) 2025-05-01
AU2009213751B2 (en) 2014-09-25
RU2504393C2 (ru) 2014-01-20
JP6618967B2 (ja) 2019-12-11
TWI442932B (zh) 2014-07-01
SI2505204T1 (sl) 2015-04-30
US10729739B2 (en) 2020-08-04
JP2024028869A (ja) 2024-03-05
JP2011511786A (ja) 2011-04-14
CY1115561T1 (el) 2017-01-04
JP2011511785A (ja) 2011-04-14
ES2540235T3 (es) 2015-07-09
KR20180118830A (ko) 2018-10-31
EA017582B1 (ru) 2013-01-30
CN101939020B (zh) 2012-12-26
US10695398B2 (en) 2020-06-30
IL207400A (en) 2014-12-31
JP5924866B2 (ja) 2016-05-25
US20240316142A1 (en) 2024-09-26
JP2016193910A (ja) 2016-11-17
US20190167755A1 (en) 2019-06-06
IL207295A0 (en) 2010-12-30
EA200901075A1 (ru) 2010-04-30
AU2009213751A1 (en) 2009-08-20
AU2009213748A1 (en) 2009-08-20
US9415085B2 (en) 2016-08-16
US9877999B2 (en) 2018-01-30
US20090203622A1 (en) 2009-08-13
TWI539959B (zh) 2016-07-01
NZ603932A (en) 2014-04-30
EA026521B1 (ru) 2017-04-28
CA3235099A1 (en) 2009-08-20
KR20140130757A (ko) 2014-11-11
SI2650012T1 (sl) 2015-06-30
TW200938217A (en) 2009-09-16
EA201300742A1 (ru) 2014-02-28
HRP20150290T1 (hr) 2015-04-10
NZ603958A (en) 2013-03-28
US20210128673A1 (en) 2021-05-06
US20220218782A1 (en) 2022-07-14
CA2714445A1 (en) 2009-08-20
WO2009101533A1 (en) 2009-08-20
EP2505204B1 (en) 2014-12-24
CN107412726A (zh) 2017-12-01
US20170290879A1 (en) 2017-10-12
CA2714444A1 (en) 2009-08-20
JP2022184898A (ja) 2022-12-13
KR20100123714A (ko) 2010-11-24
KR20100126362A (ko) 2010-12-01
IL223124A0 (en) 2012-12-31
ES2532709T3 (es) 2015-03-31
US20140349935A1 (en) 2014-11-27
HRP20140665T1 (hr) 2014-10-10
US11766468B2 (en) 2023-09-26
BRPI0908127A2 (pt) 2015-08-04
PL2505204T3 (pl) 2015-05-29
US10973870B2 (en) 2021-04-13
EP2505204A2 (en) 2012-10-03
PL2249859T3 (pl) 2014-10-31
EP2505204A3 (en) 2013-01-09
HK1176552A1 (en) 2013-08-02
IL207295A (en) 2015-03-31
KR20220009504A (ko) 2022-01-24
DK2650012T3 (da) 2015-06-15
US11826397B2 (en) 2023-11-28
TW200938218A (en) 2009-09-16
DK2249859T3 (da) 2014-06-02
JP2018039814A (ja) 2018-03-15
IL207400A0 (en) 2010-12-30
EP2249859B1 (en) 2014-04-23
EA036695B1 (ru) 2020-12-09
MX2010008816A (es) 2010-09-07
KR20250028541A (ko) 2025-02-28
ES2479441T3 (es) 2014-07-24
RU2010133480A (ru) 2012-03-20
US9579359B2 (en) 2017-02-28
EP2650012A1 (en) 2013-10-16
EA201300741A1 (ru) 2014-02-28
CN101939020A (zh) 2011-01-05
JP7400029B2 (ja) 2023-12-18
NZ587057A (en) 2012-12-21
PL2650012T3 (pl) 2015-08-31
JP2014141505A (ja) 2014-08-07
AU2009213748B9 (en) 2014-05-22
KR20150091543A (ko) 2015-08-11
NZ587088A (en) 2012-12-21
EP2249858A1 (en) 2010-11-17
EP2650012B1 (en) 2015-03-25
CY1116289T1 (el) 2017-02-08
DK2505204T3 (da) 2015-03-16
HK1145011A1 (en) 2011-03-25
RU2010133481A (ru) 2012-03-20
JP2022133426A (ja) 2022-09-13
US20220031801A1 (en) 2022-02-03
ZA201005697B (en) 2014-01-24
EP2249859A1 (en) 2010-11-17
AU2009213748B2 (en) 2014-03-13
CY1116341T1 (el) 2017-02-08
US20220226422A1 (en) 2022-07-21
JP2014167009A (ja) 2014-09-11
PT2650012E (pt) 2015-06-30
JP6189234B2 (ja) 2017-08-30
EP3360565A1 (en) 2018-08-15
CN103990107A (zh) 2014-08-20
US20200237854A1 (en) 2020-07-30
JP5876652B2 (ja) 2016-03-02
JP6254042B2 (ja) 2017-12-27
CA2714445C (en) 2018-01-16
HK1198243A1 (en) 2015-03-20
JOP20090061B1 (ar) 2021-08-17
JP2016216455A (ja) 2016-12-22
JP2025160167A (ja) 2025-10-22
BRPI0908129A2 (pt) 2015-08-04
WO2009101530A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
MX2010008817A (es) Tratamiento de cancer de prostata en etapa metastatica con degarelix.
IN2012DN02046A (es)
PL2358697T3 (pl) Związki izoindolinowe do zastosowania w leczeniu raka
EP2197533A4 (en) ABLATION OF PROSTATE CANCER
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
ZA201102362B (en) Molecular markers in prostate cancer
SI2200431T1 (sl) Sestave in metode za zdravljenje raka
MX2011011431A (es) Composicion para el tratamiento de cancer de prostata.
MY146112A (en) Long-term feed - cancer patient
IL186980A0 (en) Characterizing prostate cancer
GB0804496D0 (en) Treating cancer
EP2374463A4 (en) COMPOSITION FOR IMPROVING RADIATION THERAPY FOR CANCER
EP2137213A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER
JO3525B1 (ar) علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس
WO2008009895A3 (en) Matriptase-2
WO2009097095A9 (en) Methods for treating hematopoietic malignancies
HK1145011B (en) Treatment of metastatic stage prostate cancer with degarelix
WO2010002454A3 (en) Therapeutic combinations for use in neoplasia
AU323022S (en) Birdcage roof
GB0809730D0 (en) Improvements in the chemotherapy of cancer
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer
JO3550B1 (ar) مركب لمعالجة سرطان البروستاتا
AU2007901628A0 (en) Methods and compositions for treating prostate cancer
AU2008906236A0 (en) Prostate Cancer Treatment Rectal Probe
GB0715704D0 (en) Improvements in the chemotherapy of cancer

Legal Events

Date Code Title Description
FG Grant or registration